Your fact-checks will appear here
Clinical trials investigating the use of ivermectin in various contexts, including oncology.
Two clinical studies are publicly associated with testing , but only one—the phase I/II trial NCT05318469—has detailed, actively reported design elements: it combines oral ivermectin with an anti‑PD‑1...
Large, well-designed and major regulatory reviews conclude there is no reliable evidence that ivermectin prevents or treats outside clinical trials, while many small, low‑quality studies and activist ...
Laboratory studies identify ivermectin as a host‑directed antiviral in cell cultures—most notably by disrupting importin (IMP) α/β1–mediated nuclear transport of viral proteins—producing dose‑dependen...
There is evidence of a small number of early‑phase clinical trials testing ivermectin in cancer patients, but they are limited in number, mostly based in the United States, and focused on combination ...
Short-term side effects after a standard dose of ivermectin are usually mild and transient—most commonly itch, rash, fever, headache and gastrointestinal upset within the first few days following trea...
Ivermectin shows antiviral activity in laboratory cell cultures against SARS‑CoV‑2, but large, high‑quality clinical trials and systematic reviews have not demonstrated consistent benefit for treating...